| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| ln Vivo |
Ocular PK: After topical instillation of 1% hydrocortisone sodium phosphate eye drops (50 μL) in cataract patients, aqueous humor concentrations peaked at 30 min (Tₘₐₓ) with Cₘₐₓ = 23.8 ng/mL. AUC₀₋₁₂₀ was 1342 ng·min/mL. Elimination half-life = 46 min. Systemic absorption was negligible (plasma concentrations below detection limit).[1]
In rats with acetic acid-induced stomach ulcers, hydrocortisone sodium phosphate (2.5 mg/kg, intraperitoneal injection, daily) can postpone the healing process [2]. |
|---|---|
| Animal Protocol |
Animal/Disease Models: Wistar rat [2]
Doses: 2.5 mg/kg Route of Administration: 2.5 mg/kg, intraperitoneal (ip) injection, daily Experimental Results: Caused significant delay in healing of acetic acid-induced ulcers. |
| ADME/Pharmacokinetics |
Ocular pharmacokinetics: After topical administration of 1% hydrocortisone sodium phosphate eye drops (50 μL) to cataract patients, the aqueous humor concentration reached its peak at 30 minutes (Tₘₐₓ), Cₘₐₓ = 23.8 ng/mL. The AUC₀₋₁₂₀ was 1342 ng·min/mL. The elimination half-life was 46 minutes. Systemic absorption was negligible (plasma concentration was below the detection limit). [1]
|
| Toxicity/Toxicokinetics |
In rats with acetic acid-induced gastric ulcers, subcutaneous injection of hydrocortisone sodium phosphate (50 mg/kg/day) significantly delayed ulcer healing: the ulcer index increased to 129 ± 11, compared to 59 ± 7 in the control group (p<0.01). This resulted in severe mucosal damage, accompanied by neutrophil infiltration and edema. Body weight gain was reduced by 12% compared to the control group. [2]
441406 Rats Oral LD50 6100 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly., 21(2117), 1979 441406 Rats Intraperitoneal LD50 603 mg/kg Behavior: Somnolence (overall activity inhibition); Behavioral: Seizures or influence on seizure threshold; Behavioral: Ataxia Yakkyoku. Pharmacy., 26(379), 1975 441406 Rats Subcutaneous LD50 680 mg/kg Gekkan Yakuji. Pharmaceuticals Monthly., 21(2117), 1979 441406 Rats Intravenous LD50 632 mg/kg Behavioral studies: somnolence (overall activity inhibition); behavioral studies: seizures or influence on seizure threshold; behavioral studies: ataxia. Yakkyoku. Pharmacy, 26(379), 1975. 441406 Rat intramuscular injection LD50 1500 mg/kg. Monthly Pharmacy, 21(2117), 1979. |
| References |
[1]. Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application. Int J Clin Pract. 2021 Dec;75(12):e14987.
[2]. Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Am J Med. 1991 Aug 8;91(2A):15S-19S. |
| Additional Infomation |
Sodium hydrocortisone phosphate eye drops can rapidly penetrate the human cornea and reach therapeutic concentrations in the aqueous humor within 15 minutes of instillation. [1]
In rats, concurrent use of sucralfate/lansoprazole reversed ulcer healing impairment induced by sodium hydrocortisone phosphate. [2] Sodium cortisol phosphate is an organic sodium salt, which is the disodium salt of cortisol phosphate. It contains cortisol phosphate (2-). |
| Molecular Formula |
C21H29O8P-2.2[NA+]
|
|---|---|
| Molecular Weight |
486.40356
|
| Exact Mass |
486.139
|
| CAS # |
6000-74-4
|
| Related CAS # |
3863-59-0
|
| PubChem CID |
441406
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
669.9ºC at 760 mmHg
|
| LogP |
2.775
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
836
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
[Na+].[Na+].O=P(OCC([C@]1(CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)C3[C@H](C[C@]12C)O)=O)O)=O)([O-])[O-]
|
| InChi Key |
RYJIRNNXCHOUTQ-OJJGEMKLSA-L
|
| InChi Code |
InChI=1S/C21H31O8P.2Na/c1-19-7-5-13(22)9-12(19)3-4-14-15-6-8-21(25,17(24)11-29-30(26,27)28)20(15,2)10-16(23)18(14)19;;/h9,14-16,18,23,25H,3-8,10-11H2,1-2H3,(H2,26,27,28);;/q;2*+1/p-2/t14-,15-,16-,18+,19-,20-,21-;;/m0../s1
|
| Chemical Name |
disodium;[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
|
| Synonyms |
hydrocortisone sodium phosphate; 6000-74-4; Efcortesol; Cortisol 21-(disodium phosphate); CHEBI:5781; DTXSID5046647; 0388G963HY; DTXCID3026647;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0559 mL | 10.2796 mL | 20.5592 mL | |
| 5 mM | 0.4112 mL | 2.0559 mL | 4.1118 mL | |
| 10 mM | 0.2056 mL | 1.0280 mL | 2.0559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
